Acumen Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Acumen Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Acumen Pharmaceuticals Inc ABOS.OQ reported a quarterly adjusted loss of 35 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -44 cents. The mean expectation of six analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -49 cents to -24 cents per share.
Reported revenue was zero; analysts expected zero.
Acumen Pharmaceuticals Inc's reported EPS for the quarter was a loss of 35 cents.
The company reported a quarterly loss of $25.37 million.
Acumen Pharmaceuticals Inc shares had fallen by 10.8% this quarter and lost 6.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 3.3% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $8.00, about 75.3% above its last closing price of $1.98
This summary was machine generated from LSEG data October 26 at 01:30 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2026 | -0.39 | -0.35 | Beat |
Jun. 30 2026 | -0.37 | -0.45 | Missed |
Mar. 31 2026 | -0.40 | -0.33 | Beat |
Dec. 31 2025 | -0.45 | -0.41 | Beat |